Pasadena, Texas (PRWEB) June 25, 2015
According to court files, Kaneka Corporation has been in dispute with Xiamen Kingdomway Group Company, Pacific Rainbow International Inc., and Shenzhou Biology and Technology Co., Ltd. since March 2011, when Kaneka instituted a patent infringement action against them in the United States District Court for the Central District of California alleging infringement of Kaneka’s U.S. Patent No. 7,910,340 relating to coenzyme Q10.
On June 10, 2015, according to court files, the Federal Circuit Court of Appeals ruled that the claim construction definitions determined by the District Court in granting its summary judgment was erroneous, vacated the judgment, and remanded the case to the District Court.
Not only are the new claim construction definitions binding on the California District Court, but also on the U.S. District Court for the Southern District of Texas, where Kaneka is in dispute with Zhejiang Medicine Co. Ltd. and ZMC-USA, LLC. (collectively “Plaintiffs”) in an infringement action for the same patent. As a result of this decision, Kaneka intends to proceed to a jury trial with the case in Texas and to the discovery process with the case in California.
Kaneka Corporation v. Xiamen Kingdomway
United States District Court for the Central District of California, Case No. 2:11-cv-02389-MRP-SS
Kaneka Corporation v. Zhejiang Medicine Co., Ltd., and ZMC-USA L.L.C.,
United States District Court for the Southern District of Texas, Houston Division, Case No. 4:11-cv-01052